| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
36,340,000 |
| Market
Cap: |
40.34(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.853 - $1.95 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 3.9 |
| Insider 3/6 Months : 4.5 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Bolt Biotherapeutics is involved in immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems. Co.'s proprietary Boltbody™ ISAC (immune-stimulating antibody conjugate) approach uses immunostimulants to engage and activate myeloid cells, including macrophages and dendritic cells, that directly kill tumor cells via phagocytosis and expose tumor neoantigens to the adaptive immune system. Co.'s lead product candidate, BDC-1001, is in clinical development for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-expressing solid tumors, including those with HER2-low tumors.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
10,000 |
11,829 |
11,829 |
| Total Buy Value |
$0 |
$9,080 |
$11,241 |
$11,241 |
| Total People Bought |
0 |
1 |
1 |
1 |
| Total Buy Transactions |
0 |
2 |
3 |
3 |
| Total Shares Sold |
0 |
289,454 |
289,454 |
1,089,454 |
| Total Sell Value |
$0 |
$259,412 |
$259,412 |
$1,859,412 |
| Total People Sold |
0 |
2 |
2 |
3 |
| Total Sell Transactions |
0 |
10 |
10 |
11 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Quinn William P. |
Chief Financial Officer |
• – – |
2023-12-12 |
4 |
B |
$0.95 |
$7,125 |
D/D |
7,500 |
36,272 |
2.74 |
22% |
|
| Quinn William P. |
Chief Financial Officer |
• – – |
2023-12-06 |
4 |
B |
$0.78 |
$1,955 |
D/D |
2,500 |
28,772 |
2.66 |
24% |
|
| Engleman Edgar |
Director |
– • – |
2023-11-30 |
4 |
S |
$0.86 |
$105,614 |
I/I |
(123,079) |
251,522 |
|
-49% |
|
| Engleman Edgar |
Director |
– • – |
2023-11-29 |
4 |
S |
$0.91 |
$23,379 |
I/I |
(25,805) |
266,456 |
|
-40% |
|
| Engleman Edgar |
Director |
– • – |
2023-11-21 |
4 |
S |
$0.90 |
$1,751 |
I/I |
(1,943) |
269,587 |
|
-56% |
|
| Vivo Panda Fund, L.p. |
10% Owner |
– – • |
2023-11-21 |
4 |
S |
$0.90 |
$3,060 |
I/I |
(3,400) |
111,662 |
|
-56% |
|
| Vivo Panda Fund, L.p. |
10% Owner |
– – • |
2023-11-20 |
4 |
S |
$0.92 |
$50,324 |
I/I |
(54,700) |
113,119 |
|
-53% |
|
| Engleman Edgar |
Director |
– • – |
2023-11-20 |
4 |
S |
$0.92 |
$28,756 |
I/I |
(31,257) |
269,823 |
|
-53% |
|
| Vivo Panda Fund, L.p. |
10% Owner |
– – • |
2023-11-17 |
4 |
S |
$0.93 |
$15,209 |
I/I |
(16,354) |
136,562 |
|
-59% |
|
| Engleman Edgar |
Director |
– • – |
2023-11-17 |
4 |
S |
$0.93 |
$8,691 |
I/I |
(9,345) |
273,615 |
|
-59% |
|
| Vivo Panda Fund, L.p. |
10% Owner |
– – • |
2023-11-16 |
4 |
S |
$0.96 |
$14,400 |
I/I |
(15,000) |
143,571 |
|
-47% |
|
| Engleman Edgar |
Director |
– • – |
2023-11-16 |
4 |
S |
$0.96 |
$8,228 |
I/I |
(8,571) |
274,749 |
|
-47% |
|
| Quinn William P. |
Chief Financial Officer |
• – – |
2023-06-06 |
4 |
B |
$1.18 |
$2,161 |
D/D |
1,829 |
26,272 |
2.66 |
-41% |
|
| Novo A/s |
10% Owner |
– – • |
2022-07-13 |
4 |
S |
$2.00 |
$1,600,000 |
D/D |
(800,000) |
3,703,991 |
|
48% |
|
| Perez Edith A. |
Chief Medical Officer |
• – – |
2021-12-22 |
4 |
OE |
$2.80 |
$99,999 |
D/D |
35,714 |
37,042 |
|
- |
|
| Quinn William P. |
Chief Financial Officer |
• – – |
2021-12-08 |
4 |
B |
$4.72 |
$23,575 |
D/D |
5,000 |
20,154 |
2.74 |
-57% |
|
| Perez Edith A. |
Chief Medical Officer |
• – – |
2021-12-06 |
4 |
B |
$4.64 |
$1,907 |
D/D |
411 |
1,328 |
2.66 |
-51% |
|
| Quinn William P. |
Chief Financial Officer |
• – – |
2021-12-06 |
4 |
B |
$4.64 |
$162 |
D/D |
35 |
15,154 |
2.66 |
-51% |
|
| Perez Edith A. |
Chief Medical Officer |
• – – |
2021-06-04 |
4 |
B |
$16.65 |
$15,268 |
D/D |
917 |
917 |
2.74 |
-16% |
|
| Quinn William P. |
Chief Financial Officer |
• – – |
2021-06-04 |
4 |
B |
$16.65 |
$20,330 |
D/D |
1,221 |
15,119 |
2.74 |
-16% |
|
| Novo A/s |
10% Owner |
– – • |
2021-02-09 |
4 |
B |
$20.00 |
$8,000,000 |
D/D |
400,000 |
4,503,991 |
2.45 |
-53% |
|
| Novo A/s |
10% Owner |
– – • |
2021-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
4,027,088 |
4,103,991 |
|
- |
|
| Healy James |
Director |
– • – |
2021-02-09 |
4 |
B |
$20.00 |
$9,000,000 |
I/I |
450,000 |
2,754,437 |
2.1 |
-53% |
|
| Healy James |
Director |
– • – |
2021-02-09 |
4 |
A |
$0.00 |
$0 |
I/I |
2,304,437 |
2,304,437 |
|
- |
|
| Powell Michael |
10% Owner |
– – • |
2021-02-09 |
4 |
B |
$20.00 |
$9,000,000 |
D/D |
450,000 |
2,754,437 |
2.45 |
-53% |
|
48 Records found
|
|
Page 1 of 2 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.05 (4.31%) 
